Published Online
on May 9, 2005

A more recent version of this article appeared on May 17, 2005

This Article Full Text (PDF) All Versions of this Article: 111/19/2509    most recent 01.CIR.0000165133.84978.E2v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodríguez-Vita, J. Articles by Ruiz-Ortega, M. Search for Related Content PubMed PubMed Citation Articles by Rodríguez-Vita, J. Articles by Ruiz-Ortega, M. Related Collections Remodeling ACE/Angiotension receptors Cell signalling/signal transduction Other hypertension Mechanism of atherosclerosis/growth factors Other Vascular biology

Submitted on June 12, 2004
Revised on December 15, 2004
Accepted on January 11, 2005

Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor--Independent Mechanism

Juan Rodríguez-Vita BSc, Elsa Sánchez-López BSc, Vanesa Esteban BSc, Mónica Rupérez BSc, Jesús Egido MD, and Marta Ruiz-Ortega PhD^*

From the Vascular and Renal Research Laboratory, Fundación Jiménez Díaz, Universidad Autónoma Madrid, Madrid, Spain.

^* To whom correspondence should be addressed. E-mail: mruizo{at}fjd.es.

Background--Angiotensin II (Ang II) participates in vascular fibrosis. Transforming growth factor- (TGF-) is considered the most important fibrotic factor, and Smad proteins are essential components of the TGF- signaling system. Our aim was to investigate whether Ang II activates the Smad pathway in vascular cells and its potential role in fibrosis, evaluating connective tissue growth factor (CTGF) and extracellular matrix (ECM) proteins.

Methods and Results--Systemic infusion of Ang II into Wistar rats increased aortic Smad2, phosphorylated-Smad2, and Smad4 expression, associated with CTGF upregulation. In growth-arrested vascular smooth muscle cells, Ang II treatment for 20 minutes caused Smad2 phosphorylation, nuclear translocation of phosphorylated-Smad2 and Smad4, and increased Smad DNA-binding activity. Ang II also caused Smad overexpression and Smad-dependent gene transcription. The AT₁ antagonist losartan diminished Ang II-induced Smad activation. The blockade of endogenous TGF- did not modify the activation of Smad caused by Ang II. The p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 diminished Ang II-induced Smad2 phosphorylation. These data show that Ang II activates the Smad pathway via AT₁ receptors and MAPK activation independently of TGF-. Transient transfection with Smad7, which interferes with receptor-mediated activation of Smad2, diminished Ang II-induced CTGF promoter activation, gene and protein expression, and fibronectin and type-1 procollagen overexpression, showing that Smad activation is involved in Ang II-induced fibrosis.

Conclusions--Our results show that Ang II activates the Smad signaling system in vascular cells in vivo and in vitro. Smad proteins are involved in Ang II-induced CTGF and ECM overexpression independently of TGF-. This novel finding suggests that Smad activation could be involved in the profibrogenic effects of Ang II in vascular diseases.

Key words: angiotensin • cells • signal transduction • fibrosis

This article has been cited by other articles:

				E. J. Kuiper, R. van Zijderveld, P. Roestenberg, K. M. Lyons, R. Goldschmeding, I. Klaassen, C. J.F. Van Noorden, and R. O. Schlingemann Connective Tissue Growth Factor Is Necessary for Retinal Capillary Basal Lamina Thickening in Diabetic Mice J. Histochem. Cytochem., August 1, 2008; 56(8): 785 - 792. [Abstract] [Full Text] [PDF]

				E. L. Page, D. A. Chan, A. J. Giaccia, M. Levine, and D. E. Richard Hypoxia-inducible Factor-1{alpha} Stabilization in Nonhypoxic Conditions: Role of Oxidation and Intracellular Ascorbate Depletion Mol. Biol. Cell, January 1, 2008; 19(1): 86 - 94. [Abstract] [Full Text] [PDF]

				A. A. Ahimastos, A. Aggarwal, K. M. D'Orsa, M. F. Formosa, A. J. White, R. Savarirayan, A. M. Dart, and B. A. Kingwell Effect of Perindopril on Large Artery Stiffness and Aortic Root Diameter in Patients With Marfan Syndrome: A Randomized Controlled Trial JAMA, October 3, 2007; 298(13): 1539 - 1547. [Abstract] [Full Text] [PDF]

				M. Ruperez, R. Rodrigues-Diez, L. M. Blanco-Colio, E. Sanchez-Lopez, J. Rodriguez-Vita, V. Esteban, G. Carvajal, J. J. Plaza, J. Egido, and M. Ruiz-Ortega HMG-CoA Reductase Inhibitors Decrease Angiotensin II-Induced Vascular Fibrosis: Role of RhoA/ROCK and MAPK Pathways Hypertension, August 1, 2007; 50(2): 377 - 383. [Abstract] [Full Text] [PDF]

				M. Ruiz-Ortega, J. Rodriguez-Vita, E. Sanchez-Lopez, G. Carvajal, and J. Egido TGF-{beta} signaling in vascular fibrosis Cardiovasc Res, May 1, 2007; 74(2): 196 - 206. [Abstract] [Full Text] [PDF]

				J. Li, N. V. Campanale, R. J. Liang, J. A. Deane, J. F. Bertram, and S. D. Ricardo Inhibition of p38 Mitogen-Activated Protein Kinase and Transforming Growth Factor-{beta}1/Smad Signaling Pathways Modulates the Development of Fibrosis in Adriamycin-Induced Nephropathy Am. J. Pathol., November 1, 2006; 169(5): 1527 - 1540. [Abstract] [Full Text] [PDF]

				C. Ruster and G. Wolf Renin-Angiotensin-Aldosterone System and Progression of Renal Disease J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2985 - 2991. [Abstract] [Full Text] [PDF]

				F. Milliat, A. Francois, M. Isoir, E. Deutsch, R. Tamarat, G. Tarlet, A. Atfi, P. Validire, J. Bourhis, J.-C. Sabourin, et al. Influence of Endothelial Cells on Vascular Smooth Muscle Cells Phenotype after Irradiation: Implication in Radiation-Induced Vascular Damages Am. J. Pathol., October 1, 2006; 169(4): 1484 - 1495. [Abstract] [Full Text] [PDF]

				A. Ortega, D. Ramila, J. A. Ardura, V. Esteban, M. Ruiz-Ortega, A. Barat, R. Gazapo, R. J. Bosch, and P. Esbrit Role of Parathyroid Hormone-Related Protein in Tubulointerstitial Apoptosis and Fibrosis after Folic Acid-Induced Nephrotoxicity J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1594 - 1603. [Abstract] [Full Text] [PDF]

				D. Sorescu Smad3 Mediates Angiotensin II- and TGF-{beta}1-Induced Vascular Fibrosis: Smad3 Thickens the Plot Circ. Res., April 28, 2006; 98(8): 988 - 989. [Full Text] [PDF]

				W. Wang, X. R. Huang, E. Canlas, K. Oka, L. D. Truong, C. Deng, N. A. Bhowmick, W. Ju, E. P. Bottinger, and H. Y. Lan Essential Role of Smad3 in Angiotensin II-Induced Vascular Fibrosis Circ. Res., April 28, 2006; 98(8): 1032 - 1039. [Abstract] [Full Text] [PDF]

				J. P. Habashi, D. P. Judge, T. M. Holm, R. D. Cohn, B. L. Loeys, T. K. Cooper, L. Myers, E. C. Klein, G. Liu, C. Calvi, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, April 7, 2006; 312(5770): 117 - 121. [Abstract] [Full Text] [PDF]

				N. C. Henderson, A. C. Mackinnon, S. L. Farnworth, F. Poirier, F. P. Russo, J. P. Iredale, C. Haslett, K. J. Simpson, and T. Sethi Galectin-3 regulates myofibroblast activation and hepatic fibrosis PNAS, March 28, 2006; 103(13): 5060 - 5065. [Abstract] [Full Text] [PDF]

				M. Ruiz-Ortega, M. Ruperez, V. Esteban, J. Rodriguez-Vita, E. Sanchez-Lopez, G. Carvajal, and J. Egido Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases Nephrol. Dial. Transplant., January 1, 2006; 21(1): 16 - 20. [Abstract] [Full Text] [PDF]